|1.||Cortes, Jorge: 98 articles (12/2015 - 09/2003)|
|2.||Kantarjian, Hagop: 79 articles (12/2015 - 03/2003)|
|3.||Jabbour, Elias: 56 articles (12/2015 - 11/2006)|
|4.||Jänne, Pasi A: 52 articles (12/2015 - 01/2003)|
|5.||Pao, William: 50 articles (02/2015 - 02/2004)|
|6.||Mitsudomi, Tetsuya: 48 articles (01/2016 - 10/2003)|
|7.||O'Brien, Susan: 47 articles (11/2015 - 09/2003)|
|8.||Kantarjian, Hagop M: 46 articles (10/2015 - 05/2002)|
|9.||Baccarani, Michele: 46 articles (09/2015 - 06/2003)|
|10.||Zhang, Li: 46 articles (09/2015 - 05/2004)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/01/2009 - "The EGFR has been targeted through the development of selective tyrosine kinase inhibitors (TKIs) that have proven effective in a subset of non-small cell lung cancer (NSCLC) patients, many bearing gain-of-function EGFR mutations or egfr gene amplification. "
01/01/2014 - "This type of non-small-cell lung carcinoma more frequently involves EGFR gene abnormalities, which determine the efficacy of EGFR tyrosine kinase inhibitor therapies (EGFR TKIs). "
01/01/2015 - "Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. "
04/01/2014 - "[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]."
01/01/2015 - "EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III trials. "
06/01/2015 - "Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. "
02/01/2015 - "Cutaneous reactions, one of the most frequently observed adverse effects associated with tyrosine kinase inhibitors, can significantly affect patients' quality of life and drug adherence and represent a major therapeutic challenge to maximizing the efficacy of targeted cancer therapy. "
02/01/2014 - "Targeting EGFR with tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, progression-free survival (PFS), and quality of life. "
09/01/2014 - "Regorafenib, an orally available multitargeted tyrosine kinase inhibitor with antiangiogenic activity, has also demonstrated preclinical evidence of activity against a number of solid tumors and further studies have proven it to be effective in GISTs following failure of standard therapy, with manageable toxicity profile. "
02/28/2015 - "In tumors with activating EGFR mutations, tyrosine kinase inhibitors (TKI) are indicated as first-line treatment, although restricted to a very small target population. "
|3.||BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
09/01/2015 - "Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the outcome of chronic myelogenous leukemia in the chronic phase (CML-CP). "
02/01/2015 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the clinical outcomes of patients with chronic myeloid leukemia (CML) in the chronic phase. "
10/01/2014 - "The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many patients with chronic myeloid leukemia (CML), but some cases are resistant to this treatment. "
06/01/2014 - "The treatment of chronic myeloid leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKIs) is highly effective in reducing disease burden and prolonging overall survival in the majority of patients. "
05/01/2014 - "Treatment of chronic myeloid leukemia has been revolutionized by the development of oral tyrosine kinase inhibitors that are highly effective in managing the disease when taken consistently. "
|4.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2013 - "Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). "
08/01/2012 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the outcome of renal cell carcinoma (RCC) patients. "
02/10/2012 - "Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. "
02/10/2012 - "Complete remission with tyrosine kinase inhibitors in renal cell carcinoma."
12/01/2013 - "Although targeted therapies (ie, tyrosine kinase inhibitors and antiangiogenesis agents) are effective as first-line treatment of metastatic renal cell carcinoma (mRCC), moderate-to-severe adverse events have been reported in clinical trials of these agents. "
|5.||Lung Neoplasms (Lung Cancer)
01/01/2009 - "Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. "
08/01/2011 - "Upfront tyrosine kinase inhibitor (TKI) has proved effective for selective advanced lung cancer patients in Taiwan. "
10/01/2011 - "Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. "
07/26/2011 - "Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors."
01/01/2011 - "We have discovered a small, fusion-type tyrosine kinase EML4-ALK that is generated through a tiny inversion within the short arm of human chromosome 2. Transgenic mice expressing EML4-ALK in lung developed hundreds of lung cancer nodules soon after birth, but such nodules were readily eradicated upon treatment with an ALK inhibitor. "
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|4.||erlotinib (CP 358,774)
|6.||sorafenib (BAY 43-9006)
|7.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)